Entering text into the input field will update the search result below

Sanofi teams up with Enteris BioPharma to develop oral T2D med

Jan. 23, 2017 9:54 AM ETSanofi (SNY) StockBy: Douglas W. House, SA News Editor1 Comment
  • Privately held Enteris BioPharma initiates a feasibility study agreement with Sanofi (NASDAQ:SNY -0.2%) to develop an oral formulation of one of Sanofi's preclinical-stage peptides for the treatment of type 2 diabetes (T2D). The effort will leverage Enteris' platform Peptelligence, which is designed to increase the solubility and absorption of peptides and small molecules while reducing variability and food effects.
  • Financial terms are not disclosed.

Recommended For You

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi